AstraZeneca fuels biotech M with $1.3 billion Ardea buy

<p>LONDON (Reuters) AstraZeneca is to buy U.S. association Ardea Biosciences for $1.26 billion, giving it a new gout drug to accelerate a diseased tube in a understanding that feeds a call of MA in a biotechnology sector.
The $32 per share merger a 54 percent reward to Ardeas shutting cost on Friday is value $1 billion after deducting money hold by Ardea, a companies pronounced on Monday.
The designed squeeze shows Britains second-biggest drug builder delivering on a guarantee to step adult deal-making to repair a drug pipeline.
Research conduct Martin Mackay told Reuters final month he was looking during acquisitions in a low billions of dollars.
We are building adult momentum, Mackay pronounced on Monday. We will continue to do these outmost deals. we consider we will be articulate about some-more as a year goes on.
The categorical item cumulative by AstraZeneca is an initial drug called lesinurad, or RDEA...